Key Findings
Pin Therapeutics publicly presented PIN-5018, an oral CK1α-selective molecular glue degrader targeting adenoid cystic carcinoma (ACC), alongside its proprietary PinMARS drug discovery platform, at a Targeted Protein Degradation (TPD) forum in China. PIN-5018 is currently undergoing a Phase 1 clinical trial in South Korea with 16 patients, and the company is pursuing US FDA accelerated approval for the compound.
Technical / Clinical Details
- PIN-5018 Profile: PIN-5018 is a molecular glue degrader specifically designed to target Casein Kinase 1 alpha (CK1α). CK1α is a protein crucial for the proliferation and survival of cancer cells, and its induced degradation is expected to exert potent anti-tumor effects. Being an orally administered agent, PIN-5018 offers enhanced patient convenience and compliance.
- PinMARS Platform: Pin Therapeutics’ unique PinMARS (Pin Molecular-glue for Anti-cancer RNA Stabilization) platform is a robust technology facilitating the efficient discovery and development of molecular glue degraders. This platform enables the identification of novel E3 ubiquitin ligase recruiters and distinct protein degradation mechanisms, allowing for the targeting of previously “undruggable” proteins.
- Clinical Trial Status: PIN-5018 is, currently, in a Phase 1 dose-escalation clinical trial in South Korea, enrolling 16 patients with adenoid cystic carcinoma (ACC). The trial assesses PIN-5018’s safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity. ACC is a rare and often recalcitrant cancer with limited effective treatment options, making the potential success of PIN-5018 highly significant.
- Path to US FDA Accelerated Approval: Pin Therapeutics is actively pursuing accelerated approval from the US FDA for PIN-5018. The company is scheduled to engage with the FDA later this year to discuss its comprehensive clinical development strategy, particularly the design of its upcoming Phase 2 and Phase 3 trials in ACC.
Background & Context
Targeted Protein Degradation (TPD) technology has rapidly gained attention as an innovative approach in cancer therapy. Unlike traditional inhibitors that merely block protein activity, TPD facilitates the complete removal of disease-associated proteins, promising more potent and durable therapeutic effects. Molecular glue degraders, with their generally smaller molecular size compared to PROTACs, may offer advantages in oral bioavailability, intensifying competition in this burgeoning field.
Adenoid cystic carcinoma (ACC) is a rare cancer that can originate in various sites, including salivary glands, mammary glands, and the trachea. Advanced ACC typically carries a poor prognosis, creating a high unmet need for novel therapeutic interventions.
Strategic Significance & Outlook
The results of PIN-5018’s Phase 1 trial and the discussions with the FDA are critically important for the future of Pin Therapeutics’ TPD pipeline. Should positive data emerge and a clear development pathway with the FDA be established, PIN-5018 could represent a groundbreaking first-in-class oral molecular glue degrader for ACC patients. This advancement would demonstrate the potential of TPD technology to provide effective solutions for rare, intractable cancers, accelerating molecular glue degrader development across the industry.
Source: https://www.koreabiomed.com/news/articleView.html?idxno=32963
Get our weekly technology intelligence — free
Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.
Subscribe Free — Weekly Tech Intelligence
By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.
- Your email and selected fields are used only to deliver the newsletter.
- We never share your information with third parties.
- You can unsubscribe anytime via the link in each email.
See our Privacy Policy for details.
Takes about a minute · Unsubscribe anytime
Comments